An investment case for maternal and neonatal tetanus elimination

被引:3
|
作者
Laing, Sarah K. [1 ]
Griffiths, Ulla [2 ]
Raza, Azhar Abid [2 ]
Zulu, Flint [2 ]
Yakubu, Ahmadu [3 ]
Bessias, Sophia [4 ]
Ozawa, Sachiko [5 ,6 ]
机构
[1] Duke Univ, Duke Global Hlth Inst, Durham, NC USA
[2] UNICEF, Hlth Sect, New York, NY USA
[3] UNICEF, Immunizat Coverage & Equ, New York, NY USA
[4] Univ N Carolina, Enterprise Analyt & Data Sci, Hlth Care, Chapel Hill, NC 27515 USA
[5] Univ N Carolina, Div Practice Adv & Clin Educ, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA
[6] Univ N Carolina, Dept Maternal & Child Hlth, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA
关键词
Tetanus; Maternal child health; Neonatal mortality; Vaccination; Elimination; Cost-effectiveness; COST-EFFECTIVENESS; NEWBORN BABIES; HEALTH-CARE; IMMUNIZATION; INTERVENTIONS; PREVENTION; STRATEGIES; DELIVERY;
D O I
10.1016/j.vaccine.2019.11.052
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Globally, 13 countries have yet to eliminate maternal and neonatal tetanus. While efforts have improved access to tetanus toxoid containing vaccines (TTCVs) and increased clean delivery practices, reaching elimination targets (<1 case of neonatal tetanus per 1000 live births per district per year) may require significant resources to reach the remaining high risk and hard-to-reach districts. Methods: We estimated the cost to achieve maternal and neonatal tetanus elimination (MNTE) in three years in the remaining 13 countries: Afghanistan, Angola, Central African Republic, Democratic Republic of the Congo, Guinea, Mali, Nigeria, Pakistan, Papua New Guinea, Somalia, South Sudan, Sudan, and Yemen. Costs were estimated for: (1) vaccination campaigns using standard TTCVs and TT-Uniject (TM) targeting women of reproductive age in high risk areas, (2) additional vaccinations delivered to pregnant women at antenatal care (ANC) clinics, (3) clean delivery and umbilical cord care promotion, (4) neonatal tetanus surveillance strengthening, and (5) validation activities. We forecasted the averted mortality to assess the cost-effectiveness of achieving MNTE. Results: It will cost an estimated US$197.7 million to realize MNTE over three years. These costs include $161.4 million for vaccination campaigns, $6.1 million for routine vaccination during ANC, $23.3 million for promotion of clean delivery practices, $4 million for surveillance, and $3 million for validation of MNTE. Achieving MNTE will avert approximately 70,000 neonatal deaths over ten years of vaccine protection, resulting in approximately 4.4 million life years gained. It will cost $2,900 per death averted and $45 per life year gained. Conclusion: Maternal and neonatal tetanus can be eliminated with significant financial investment, high prioritization, and strong political will. While substantial costs must be incurred to reach hard-to-reach populations, MNTE should be accomplished as a matter of health equity, and will significantly contribute to reaching the United Nations' Sustainable Development Goals. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2241 / 2249
页数:9
相关论文
共 50 条
  • [1] Maternal and neonatal tetanus elimination: from protecting women and newborns to protecting all
    Khan, Rownak
    Vandelaer, Jos
    Yakubu, Ahmadu
    Raza, Azhar Abid
    Zulu, Flint
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2015, 7 : 171 - 180
  • [2] Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative
    Vandelaer, J
    Birmingham, M
    Gasse, R
    Kurian, M
    Shaw, C
    Garnier, S
    VACCINE, 2003, 21 (24) : 3442 - 3445
  • [3] India is on the way forward to maternal and neonatal tetanus elimination!
    Bairwa, Mohan
    Shashikantha, S. K.
    Rajput, Meena
    Khanna, Pardeep
    Malik, Jagbir Singh
    Nagar, Mukesh
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (08) : 1129 - 1131
  • [4] Sustaining Maternal and Neonatal Tetanus Elimination (MNTE) in countries that have been validated for elimination - progress and challenges
    Yusuf, Nasir
    Steinglass, Robert
    Gasse, Francois
    Raza, Azhar
    Ahmed, Bilal
    Blanc, Diana Chang
    Yakubu, Ahmadu
    Gregory, Christopher
    Tohme, Rania A.
    BMC PUBLIC HEALTH, 2022, 22 (01)
  • [5] Sustaining Maternal and Neonatal Tetanus Elimination (MNTE) in countries that have been validated for elimination – progress and challenges
    Nasir Yusuf
    Robert Steinglass
    Francois Gasse
    Azhar Raza
    Bilal Ahmed
    Diana Chang Blanc
    Ahmadu Yakubu
    Christopher Gregory
    Rania A. Tohme
    BMC Public Health, 22
  • [6] Towards tetanus elimination
    Ibrahim, Hamdy
    Zaky, Samy
    Hagag, Mahmoud
    Bahawashy, Ahmed S. El
    Elsawy, Mohamed
    EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2025, 37 (01)
  • [7] Maternal and neonatal tetanus
    Thwaites, C. Louise
    Beeching, Nicholas J.
    Newton, Charles R.
    LANCET, 2015, 385 (9965) : 362 - 370
  • [8] Tetanus toxoid vaccine: Elimination of neonatal tetanus in selected states of India
    Verma, Ramesh
    Khanna, Pardeep
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (10) : 1439 - 1442
  • [9] Serological Monitoring Is Key To Sustain Progress of the Maternal and Neonatal Tetanus Elimination Initiative
    Levine, Myron M.
    Pasetti, Marcela F.
    CLINICAL AND VACCINE IMMUNOLOGY, 2016, 23 (07) : 532 - 534
  • [10] Process of neonatal tetanus elimination in Nepal
    Vandelaer, Jos
    Partridge, Jeffrey
    Suvedi, Bal Krishna
    JOURNAL OF PUBLIC HEALTH, 2009, 31 (04) : 561 - 565